Skip to main content
Lasa Supergenerics Limited logo

Lasa Supergenerics Limited — Investor Relations & Filings

Ticker · LASA ISIN · INE670X01014 LEI · 984500B9EA5EC3R2F726 BSE.NS Manufacturing
Open in API
Filings indexed 464 across all filing types
Latest filing 2020-06-05 Regulatory Filings
Country IN India
Listing BSE.NS LASA

About Lasa Supergenerics Limited

https://lasalabs.com/

Lasa Supergenerics Limited is a vertically integrated manufacturer specializing in Active Pharmaceutical Ingredients (APIs) for both veterinary and human health applications. The company focuses on the research, development, and production of high-quality chemical intermediates and APIs. Its core product portfolio includes a significant range of anthelmintics, such as Albendazole, Fenbendazole, and Ricobendazole, alongside other specialized therapeutic categories. Utilizing advanced manufacturing facilities and a dedicated research and development wing, the organization emphasizes cost-effective production processes and stringent quality control standards. Lasa Supergenerics Limited serves a global clientele, providing essential components for pharmaceutical formulations and animal health products through its expertise in complex chemical synthesis and large-scale manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Regulatory Filings
2020-06-05 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a notice of a Board Meeting scheduled to consider and approve audited financial results and the auditor's report for the quarter and year ended March 31, 2020. It is an intimation to stock exchanges and public about the upcoming board meeting, not the actual financial results or auditor's report. The document is short (1856 characters) and serves as a meeting notice rather than a report. Therefore, it fits the category of Board/Management Information (MANG), which includes announcements of board meetings and related information.
2020-05-28 English
Updates
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming dematerialization of securities for the quarter and year ended March 31, 2020. It is addressed to stock exchanges and signed by the company secretary and the registrar and share transfer agent. The document is short (3026 characters) and serves as a compliance certificate rather than a financial report or detailed filing. It does not contain financial statements or detailed analysis but is a regulatory compliance certificate. Therefore, it fits best under Regulatory Filings (RNS) as a regulatory announcement and certification rather than a full report or announcement of voting results, management changes, or capital updates.
2020-05-19 English
Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing about the company's efforts to support the fight against Covid-19, including distribution of medicines and sanitization supplies. It is an informational announcement to stakeholders rather than a financial report, regulatory filing, or any formal report type. The document length is short (1621 characters) and does not contain financial data, management changes, voting results, or any regulatory compliance content. It is best classified as a general Regulatory Filing (RNS) since it is a miscellaneous announcement that does not fit other specific categories.
2020-05-14 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a media release announcing that Lasa Supergenerics Ltd has received FDA approval to manufacture progesterone. It discusses the company's new product launch, market potential, and strategic plans. There are no financial statements, regulatory filings, or detailed financial data. The document is a press release or media announcement rather than a formal financial report or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The closest fitting category is Regulatory Filings (RNS) as a general announcement to the stock exchanges and public about a significant company development that does not fall into other specific categories.
2020-04-13 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 95% confidence The document is a disclosure under Regulation 30(2) of the Securities Exchange Board of India (SEBI) (Securities Acquisition of Shares and Takeover) Regulations, 2011. It details the shareholding of a promoter (Dr. Omkar P. Herlekar) and persons acting in concert, indicating a substantial acquisition of shares or change in shareholding. The document is addressed to stock exchanges and is a formal notification of shareholding changes rather than a financial report or earnings release. It does not contain financial statements or management discussion but is a regulatory disclosure about shareholding. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is under 5,000 characters and is a direct disclosure, not an announcement of a report or certification. Confidence is high due to clear reference to SEBI takeover regulations and shareholding details.
2020-04-07 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.